Related Experiment Video
Updated: May 23, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
High-Risk HPV Oncoproteins and PD-1/PD-L1 Interplay
Shuai Zhen1,2
1Center for Translational Medicine, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, PR China.
Abstract:
Human papillomavirus (HPV) related cancers often arise from a background of chronic inflammation. Systemic treatment for advanced HPV-related cancers has been disappointing due to their strong resistance to chemotherapy and even to tyrosine kinase inhibitors (TKIs). Recently, the use of immune checkpoint inhibitor (ICI) therapy has revolutionized the systemic treatment of advanced HPV-related cancers. For the first time, clinical trials testing ICIs, anti-CTLA-4, and anti-PD1/PDL1 reported a survival benefit in patients with sorafenib resistance. However, it took a long time to find the right combination regimen to use ICIs in combination with the antiangiogenic agent bevacizumab to substantially prolong overall survival (OS) of patients with advanced HPV-related cancer after sorafenib. This review provides a comprehensive history of ICI therapy in HPV-related cancer, up-to-date information on the latest ICI clinical trials, and discusses the recent development of novel ICIs that would potentially lead to a new checkpoint blockade therapy for advanced HPV-related cancer.
More Related Videos
13:56A Comparative Approach to Characterize the Landscape of Host-Pathogen Protein-Protein Interactions
Published on: July 18, 2013
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
Related Concept Videos
Abnormal Proliferation
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Tumor Immunotherapy
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...